Testing a new daily pill for hard-to-treat lymphoma linked to Epstein-Barr virus

Plain-English translation of NCT06789159 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called to see if it is safe and helps people whose aggressive B-cell lymphoma (a type of blood cancer) has returned or stopped responding to previous treatments, and whose cancer is linked to Epstein-Barr virus infection. Researchers will test three different daily doses of the medication to find the right balance between effectiveness and side effects. You would take this medication by mouth every day for 28-day cycles, with break periods for monitoring.

People with relapsed or refractory lymphoma linked to Epstein-Barr virus have limited treatment options after standard therapies stop working. This medication is designed to target this specific type of lymphoma, and this trial will determine whether it is safe enough and promising enough to help future patients.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with aggressive B-cell lymphoma that has come back or stopped responding to at least two previous treatment regimens
your cancer is linked to Epstein-Barr virus infection
you have exhausted standard treatment options that might help you
your blood counts and organ function (liver, kidney) are adequate or have recovered from prior treatment side effects
you can attend regular clinic visits and follow study procedures for up to 3 years

You likely don't qualify if…

you have severe or unstable heart or lung disease, or recently had heart problems
you have active cancer involvement in your brain or spinal fluid
you are currently taking herbal supplements or medications that interact with how your body processes this drug
you have a serious active infection or uncontrolled medical condition that would make it unsafe to receive this medication
you are pregnant or planning to become pregnant during the study

What participation looks like

You would take the medication by mouth once daily for 28 days, then have a break while doctors check how your cancer is responding. This cycle repeats every 4 weeks as long as the medication is helping and side effects are manageable. You'll have regular clinic visits and blood tests to monitor your health and how well the treatment is working, with formal disease assessments every 3 cycles. All participants are followed for 3 years total, even after stopping the medication.

AI-generated summary from trial data · Jul 16, 2026 · Not medical advice

Trial locations(1 site)

United States

University of Kentucky, Lexington, Kentucky